Adaptimmune Therapeutics (ADAP) News Today $1.39 +0.09 (+6.92%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 2:02 AM | insidermonkey.comWhy Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?July 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune on Revolutionary T-cell Therapy Prospects and Strong Sales ForecastJuly 16, 2024 | americanbankingnews.comShort Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Increases By 15.1%July 15, 2024 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Up 15.1% in JuneAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 5,640,000 shares, a growth of 15.1% from the June 15th total of 4,900,000 shares. Based on an average daily trading volume, of 1,570,000 shares, the short-interest ratio is currently 3.6 days.July 3, 2024 | investorplace.com3 Biotech Moonshots With Imminent Catalyst PotentialJuly 3, 2024 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest UpdateAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 4,900,000 shares, a growth of 6.1% from the May 31st total of 4,620,000 shares. Based on an average daily volume of 1,480,000 shares, the days-to-cover ratio is presently 3.3 days.June 19, 2024 | insidertrades.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Insider Cintia Piccina Sells 24,531 SharesJune 18, 2024 | marketbeat.comCintia Piccina Sells 24,531 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) StockAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) insider Cintia Piccina sold 24,531 shares of Adaptimmune Therapeutics stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $0.93, for a total value of $22,813.83. Following the sale, the insider now directly owns 38,293 shares in the company, valued at $35,612.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.May 30, 2024 | globenewswire.comGalapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsMay 29, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Passes Below 50-Day Moving Average of $1.21Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Passes Below 50 Day Moving Average of $1.21May 23, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cooper Co (COO), Neurocrine (NBIX) and Arcturus Therapeutics (ARCT)May 20, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday TradingMay 17, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) PT Lowered to $3.00 at MizuhoMizuho cut their target price on shares of Adaptimmune Therapeutics from $9.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday.May 17, 2024 | marketbeat.comLeerink Partnrs Weighs in on Adaptimmune Therapeutics plc's Q2 2024 Earnings (NASDAQ:ADAP)Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q2 2024 earnings per share estimates for Adaptimmune Therapeutics in a research report issued to clients and investors on Wednesday, May 15th. Leerink Partnrs analyst J. ChangMay 16, 2024 | msn.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call TranscriptMay 15, 2024 | investorplace.comADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | msn.comAdaptimmune Q1 2024 Earnings PreviewMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Fate Therapeutics (FATE) and Instil Bio (TIL)May 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)April 29, 2024 | finance.yahoo.comGlobal CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & PhaseApril 26, 2024 | seekingalpha.comAdaptimmune: Huge Opportunity Amid Their Setback With GenentechApril 26, 2024 | bizjournals.comGenentech parent Roche has cut 20% of risky drugs from pipeline and is adjusting its workforce to matchApril 24, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 5.3% Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 5.3%April 24, 2024 | money.usnews.comAdaptimmune Therapeutics Plc - ADRApril 24, 2024 | finance.yahoo.comGarry Menzel joins GHO Capital as Operating PartnerApril 19, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week DownApril 19, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Up 12.4%Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Up 12.4%April 16, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 4.8% Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 4.8%April 16, 2024 | markets.businessinsider.comMaintaining Buy Rating on Adaptimmune Therapeutics Post-Genentech Collaboration TerminationApril 12, 2024 | bizjournals.comAdaptimmune shares drop as Genentech terminates potential $3B dealApril 12, 2024 | msn.comAdaptimmune falls as Roche strategic collaboration endsApril 11, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Up 3.9%Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Up 3.9%April 11, 2024 | marketbeat.comBaillie Gifford & Co. Sells 1,235,269 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP)Baillie Gifford & Co. lowered its holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 7.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,912,140 shares of the biotechnologyApril 1, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 3.8% Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 3.8%April 1, 2024 | marketbeat.comShort Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Expands By 11.1%Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 3,110,000 shares, a growth of 11.1% from the February 29th total of 2,800,000 shares. Based on an average daily volume of 1,850,000 shares, the days-to-cover ratio is currently 1.7 days.March 26, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 2.1%Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 2.1%March 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)March 22, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Trading 4.5% Higher Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Up 4.5%March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)March 21, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.33Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.33March 18, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 6.1% Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 6.1%March 15, 2024 | benzinga.comPeter W. Sonsini's Net WorthMarch 15, 2024 | finance.yahoo.comADAP Sep 2024 2.500 putMarch 14, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.59Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.59March 13, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday TradingMarch 13, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.49Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.49March 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)March 11, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 4%Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Down 4%March 8, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Sees Unusually-High Trading VolumeAdaptimmune Therapeutics (NASDAQ:ADAP) Sees Unusually-High Trading VolumeMarch 8, 2024 | seekingalpha.comAdaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here ADAP Media Mentions By Week ADAP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAP News Sentiment▼1.260.62▲Average Medical News Sentiment ADAP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAP Articles This Week▼32▲ADAP Articles Average Week Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PGEN News BLUE News CLLS News FATE News ATRA News RLAY News IRON News COLL News CNTA News ANAB News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
